Oncologia

Estudo de caso-controle | Associação entre antraciclinas e insuficiência cardíaca em pacientes tratados para câncer de mama ou linfoma, 1985-2010

7 Fev, 2023 | 15:26h

Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010 – JAMA Network Open

Comentário convidado: Heart Failure in Patients With Cancer Treated With Anthracyclines—Revisiting the Foundation of Cardio-Oncology- JAMA Network Open

 

Comentário no Twitter

Anthracycline is linked to double the rate of heart failure in patients with cancer vs matched controls, 7.4% at 15 years. https://t.co/SxlJkJ7oLR

— JAMA Network Open (@JAMANetworkOpen) February 3, 2023

 

---

M-A | Risco de segundo câncer primário entre pacientes com câncer de mama

7 Fev, 2023 | 15:14h

Risk of second primary cancer among breast cancer patients: A systematic review and meta-analysis – Frontiers in Oncology

 

---

Revisão sistemática | Não há evidências suficientes para recomendar corticosteroides no tratamento da fadiga relacionada ao câncer

31 Jan, 2023 | 12:16h

Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer – Cochrane Library

Resumo: What are the benefits and risks of using corticosteroid medicines in the treatment of fatigue related to advanced cancer? – Cochrane Library

 

---

Estudo randomizado | Temozolomida adjuvante com ou sem interferon alfa em pacientes com gliomas de alto grau recém-diagnosticados

31 Jan, 2023 | 11:55h

Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial – JAMA Network Open

Comentário: Interferon Alfa Improves Upon Standard Care in High Grade Glioma – Cancer Therapy Advisor

 

Comentário no Twitter

This phase 3 clinical trial demonstrated interferon alfa + temozolomide prolonged survival time in patients with newly diagnosed high-grade gliomas by median 8 months (18% vs 9% 5yr overall survival), especially with MGMT promoter unmethylated tumors. https://t.co/2yOssnF97G

— JAMA Network Open (@JAMANetworkOpen) January 27, 2023

 

---

Estudo de coorte | Risco de neoplasias malignas do trato gastrintestinal após transplante de medula óssea

31 Jan, 2023 | 11:53h

Malignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow Transplant – JAMA Oncology (link para o resumo – $ para o texto completo)

Comentário: Risk of Subsequent Gastrointestinal Tract Malignancies After Blood or Marrow Transplantation – The ASCO Post

 

Comentário no Twitter

Exposure to cytarabine, etoposide and anthracyclines & chronic graft vs. host disease increase risk of colorectal, liver & esophageal cancer after BMT, providing evidence for appropriate evaluation & management in high-risk populations. https://t.co/UENFM1UWRw

— JAMA Oncology (@JAMAOnc) January 23, 2023

 

---

Diretriz AHA | Hipertensão relacionada ao tratamento oncológico

23 Jan, 2023 | 13:46h

Cancer Therapy–Related Hypertension: A Scientific Statement From the American Heart Association – Hypertension

Principais tópicos a saber: Cancer Therapy-Related HTN – American Heart Association

Comentário: Cancer and hypertension induced by anticancer drugs: The need for increased awareness, improved detection and proactive management – American Heart Association

 

---

Estudo de coorte | Prevalência da neoplasia colorretal 10 ou mais anos após uma colonoscopia de rastreamento negativa em 120.000 repetições desses exames

23 Jan, 2023 | 13:34h

Prevalence of Colorectal Neoplasia 10 or More Years After a Negative Screening Colonoscopy in 120 000 Repeated Screening Colonoscopies – JAMA Internal Medicine

Comentários:

Prevalence of Colorectal Cancers Low 10 Years Following Negative Screening Test – HCP Live

Risk for Advanced Neoplasm Low 10+ Years After Negative Colonoscopy – HealthDay

 

Comentário no Twitter

Large registry-based study finds strong potential for risk-adapted #colorectalcancer screening, suggests extension of screening endoscopy intervals beyond 10 years may be warranted particularly in asymptomatic female and younger participants. https://t.co/fChg6DRyPw @DKFZ

— JAMA Internal Medicine (@JAMAInternalMed) January 17, 2023

 

---

Diretriz | Tratamento do câncer de próstata metastático sem castração e sensível à castração

23 Jan, 2023 | 13:29h

2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer – Canadian Urological Association Journal (PDF aqui)

Ver também: Summary of changes (PDF aqui)

Conteúdo relacionado: 2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) – Canadian Urological Association Journal

 

---

Câncer de pulmão de não pequenas células metastático não dependente de oncogene: diretriz ESMO para diagnóstico, tratamento e seguimento

23 Jan, 2023 | 13:27h

Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up – Annals of Oncology

 

---

Estudo randomizado | Adjuvante S-1 comparado com observação no câncer ressecado do trato biliar

23 Jan, 2023 | 13:17h

Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

New @TheLancet – Nakachi et al – Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial https://t.co/E6y7a9dWNf#gitwitter #biliarytractcancer #onctwitter @OncoAlert #JCOG pic.twitter.com/WEBFXjIWce

— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) January 20, 2023

 

---